CliffBio
small molecule

ACTOPLUS MET XR

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameACTOPLUS MET XR
Active ingredientMETFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Strength1GM;EQ 30MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
7959946July 2026product
7785627July 2026product

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ACTOPLUS MET XR patent cliff — loss of exclusivity July 2026 | CliffBio